Perioperative Guide
EnglishJapanese
Quick read

Device lead-associated TR: why the team matters

A pacemaker or ICD lead crossing the tricuspid valve can cause or worsen TR by interfering with leaflet motion. But lead presence alone does not prove causality. This pathway requires device and valve expertise together.

An echo report says 'possible lead impingement on the tricuspid leaflet.' The next question is not just whether the TR is severe. The question is whether the lead is part of the mechanism — and if it is, what that means for device management, valve management, and procedural risk.

Key takeaway

Device lead-associated TR cannot be managed by severity grade alone. Lead-valve interaction, pacing dependence, extraction or revision risk, and valve intervention options all require joint device-valve team evaluation.

Key points

  • A transvenous RV lead crossing the tricuspid valve can cause leaflet impingement, restriction, perforation, adhesion, entrapment, or malcoaptation.
  • Lead presence does not prove lead-caused TR. Functional TR from RV dysfunction, pulmonary hypertension, annular dilation, left-sided disease, or chronic RV pacing may coexist.
  • Severity grading still matters, but the next step cannot be separated from device management.
  • Lead extraction, revision, repositioning, or alternative pacing strategies each require dedicated risk assessment.
  • Valve repair, replacement, T-TEER, or TTVR in the presence of a lead requires specialized planning.
  • The TR Severity Tool grades regurgitation severity. The TR Intervention Navigator routes this mechanism to device-valve team evaluation.
  • Neither tool recommends extraction, revision, repositioning, or a specific valve procedure.

When to read this

Read this when a patient with a pacemaker or ICD has significant or severe TR, especially when echo suggests leaflet impingement, restricted leaflet motion, a jet originating near the lead, or possible lead-related malcoaptation.

How a transvalvular lead can cause TR

A transvenous RV lead passes from the right atrium across the tricuspid valve into the right ventricle. Depending on lead position, lead bulk, dwell time, and valve anatomy, the lead may interfere with valve closure.

  • Leaflet impingement — the lead physically prevents full leaflet coaptation
  • Restricted leaflet motion — the lead fixes a leaflet in a partially open position
  • Leaflet perforation — direct injury, more common with older leads or lead entrapment
  • Adhesion or entrapment — fibrotic tissue binds the lead to the leaflet or subvalvular apparatus
  • Malcoaptation — the lead occupies the coaptation zone, leaving a gap between leaflets

Echo clues include a leaflet fixed near the lead, restricted posterior or septal leaflet motion, a regurgitant jet tracking along the lead, or visible leaflet perforation or adherence.

The hard part: lead-associated or functional TR?

Seeing a lead does not prove the lead is the cause. Many patients with transvalvular leads also have functional TR from RV dilation, pulmonary hypertension, left-sided heart disease, annular dilation, pacing-induced cardiomyopathy, or chronic RV pacing.

Attributing all TR to the lead may overestimate what lead revision can fix. Ignoring the lead may miss a mechanical mechanism that changes the treatment plan.

The key question is not only 'how severe is the TR?' It is 'how much is the lead contributing to the mechanism?'

Why a device-valve team is needed

The device team evaluates lead type, dwell time, lead integrity, pacing dependence, extraction risk, and options for revision or alternative pacing. The valve team evaluates TR severity, leaflet anatomy, annular geometry, RV function, surgical options, and transcatheter options.

Neither perspective is enough alone. Decisions about extraction, revision, leadless pacing, epicardial leads, valve repair, valve replacement, T-TEER, or TTVR require shared planning.

What this tool does not do

The TR Intervention Navigator does not recommend lead extraction, lead revision, lead repositioning, valve repair, valve replacement, T-TEER, or TTVR. It identifies the correct pathway: suspected device lead-associated TR should be evaluated by a device-valve team rather than pushed through a standard TR pathway. The final management plan is individualized.

Perioperative considerations

For noncardiac surgery, preoperative assessment should include pacing dependence, recent device interrogation, RV function, pulmonary pressure context, venous congestion, hepatic and renal function, and volume status.

For major surgery or cardiac surgery, intraoperative TEE should specifically assess lead-valve interaction, TR severity under changing loading conditions, RV response, and the effect of positive-pressure ventilation, fluid administration, and pulmonary vascular resistance.

  1. Addetia K, Harb SC, Hahn RT, Kapadia S, Lang RM. Cardiac Implantable Electronic Device Lead-Induced Tricuspid Regurgitation. JACC Cardiovasc Imaging. 2019.
  2. Otto CM, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease. J Am Coll Cardiol. 2021;77(4):e25–e197.

Apply this in practice

Use the TR Intervention Navigator to evaluate the appropriate pathway for device lead-associated TR.

Open TR Intervention Navigator

See also